Hims & Hers shares jumped nearly 50% in premarket trade on Monday after a report it has ended a dispute with Novo Nordisk by striking a partnership with the Danish drug giant.
FlashNews:
What Makes a Modern Investment Company Different From Traditional Financial Institutions?
Veritron Compliance Group Launches To Address Growing Digital Compliance Crisis
Ariana Grande leaves problems at home as her tour hits the UK
Singapore Inc hopes AI access will stop finance high-flyers moving to Hong Kong
BBC seeks to subpoena family members in Panorama lawsuit
The moment I knew: I heard her beautiful laugh again, and all my emotions came flooding back
Bybit adds Unitree, Moonshot AI to pre-IPO perpetuals lineup
Tokenized stock holders more than double as monthly volume surges
Israeli strikes kill 11 in Lebanon two months into truce
DataShyre Expands Consent Management for Ecommerce to Help Retailers Build Customer Trust and Drive Growth
DataShyre Expands Consent Management for Financial Services With Automated, Permissioned Data Governance
US, Canada Still See Sticking Points Before Deadline for 50% Tariffs
Is Fortuno Markets Safe? Here Are Its Key Fund Protection Systems
‘The bar here is low’: the best (and worst) supermarket brioche burger buns, tasted and rated
Island Challenge Jamaica: Adventure for Neonatal and Paediatric Care
Retrospec Joe Rev 2 Review (2026): Putting the ‘Joy’ in Joyride
This Beautifully Weird Necklace Is Secretly a USB Drive
New Urban Fiction Title Introduces a Powerhouse Female Lead
When the Story You Know Ends, Another One Begins: Jack Duin’s Debut Memoir The Eventual Outcome Arrives Now
Home » Hims & Hers stock rockets on reported end to Novo Nordisk weight-loss drug dispute